Navigation Links
Telik Announces Presentation and Webcast at Needham Biotechnology Conference
Date:6/5/2008

PALO ALTO, Calif., June 5 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced that company management will provide a corporate overview at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference in New York City on Wednesday, June 11, 2008 at 10:00 a.m. Eastern time (7:00 a.m. Pacific time). A live and archived webcast of the presentation will be available on the Telik website, http://www.telik.com.

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates.


'/>"/>
SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Telik Announces First Quarter 2008 Financial Results
2. Telik Presents Preclinical Data at 99th Annual Meeting of the American Association for Cancer Research
3. Telik Announces Fourth Quarter and 2007 Year End Financial Results and 2008 Guidance
4. Telik Announces Revised Date for Year-End Financial Release, Conference Call and Webcast
5. Telik Announces Year-End Financial Release, Conference Call and Webcast
6. Telik Announces Presentation and Webcast at JPMorgan Healthcare Conference
7. Telik Announces Presentation and Webcast at UBS Global Life Sciences Conference
8. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
9. Biopure Announces MHRA Meeting Update
10. BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
11. Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer ... that they have entered into a multiyear collaboration to identify and characterize novel ... additional tools for gene editing across all applications. , Under the terms of ...
(Date:10/12/2017)... ... 12, 2017 , ... BioMedGPS announces expanded coverage of SmartTRAK ... module, US Hemostats & Sealants. , SmartTRAK’s US Market for Hemostats and Sealants ... sealants and biologic sealants used in surgical applications. BioMedGPS estimates the market will ...
(Date:10/12/2017)... Diego, CA (PRWEB) , ... ... ... (https://www.onramp.bio/ ) has launched Rosalind™, the first-ever genomics analysis platform specifically ... all bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced ... will feature emerging and evolving technology through ... Innovation Summits will run alongside the expo portion of ... sessions, panels and demonstrations focused on trending topics within ... advanced design and manufacturing event will take place June ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
Breaking Biology News(10 mins):